Some price transparency tools aim to provide real-time healthcare information to patients’ on their out-of-pocket costs, deductibles, and information on variation between certain physicians and providers. As important as this information is, tools of this type are not widely available. The panelists also discussed the relevance of the available information, and whether it is making a difference for consumers, as well as for providers in terms of contracting and overall expenditures.
Castlight Health and Truven Health Analytics, among others, offer price transparency tools that allow patients to track their out-of-pocket costs, deductibles, and other relevant information in real time. Such technology is a big step forward, explains Ateev Mehrotra, MD, MPH, associate professor of health care policy and medicine at Harvard Medical School and hospitalist at Beth Israel Deaconess Medical Center. Yet, says Dr Mehrotra, survey data show “the vast majority of people…trying to shop for care aren’t using such websites because their employer doesn’t have them available or they don’t even know about it….It just doesn’t really work.”
To the extent possible, some of these price transparency tools are designed to couple the costs and the out-of-pocket costs with quality, explains Arthur Vercillo, MD, FACS, a surgeon and regional president of Excellus Blue Cross Blue Shield. Dr Vercillo asks, “What if having an arthroscopy is going to be 20% less in one place versus another, but the infection rate is 10% higher?” This type of data is what truly matters to patients.
Francois de Brantes, MS, MBA, executive director, Healthcare Incentives Improvement Institute, believes pricing transparency has truly changed negotiations with providers and affected spending. Available data are making a difference in terms of contracting and overall expenditures, he says, and although the amount of data as well as their relevance will vary, “The core of the information exists.” Mr de Brantes explains how state legislations are trying free up information so entrepreneurs can then make tools readily available to consumers as well as providers.
There is a potential downside of having a lot of previously unavailable information, says Dr Mehrotra, who is “just struck with the knowledge that the hospital down the street is getting paid 20% more than I.” Dr Vercillo acknowledges that “Providers are all curious as to where they stand relative to their peers in terms of not just cost, but quality also,” and will eventually use those data to their advantage.
POSITIVE Trial Update on Patients With Breast Cancer Attempting Pregnancy
December 8th 2023At last year’s San Antonio Breast Cancer Symposium, POSITIVE trial primary outcome data were presented on breast cancer–free interval, with women who paused endocrine therapy to attempt pregnancy having a similarly small rate of recurrence vs external controls from the SOFT and TEXT trials: 8.9% vs 9.2%.
Read More
Emily Goldberg Shares Insights as a Genetic Counselor for Breast Cancer Risk Screening
October 30th 2023On this episode of Managed Care Cast, Emily Goldberg, MS, CGC, a genetic counselor at JScreen, breaks down how genetic screening for breast cancer works and why it is so important to increase awareness and education around these screening tools available to patients who may be at risk for cancer.
Listen
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
What We’re Reading: RSV Vaccine Demand; Permanent Contraception; Drug Negotiation Impact
December 8th 2023The Biden administration recently met with manufacturers of respiratory syncytial virus (RSV) immunizations to encourage them to increase access to the vaccine; since the Dobbs v Jackson decision, many patients have been seeking more permanent reproductive health care solutions; a Mathematica analysis showed that Medicare prescription drug price negotiations could have cut seniors’ out-of-pocket costs by nearly a quarter had the program been in effect in 2021.
Read More
Patients With RA in Remission Withdrawing From TNF Inhibition Show Flare Increases
December 8th 2023New data presented at ACR 2023 highlighted the differences in rates of flares and Boolean 2.0 remission rates compared to patients with rheumatoid arthritis who continued a tumor necrosis factor inhibitor (TNFi).
Read More